Last Updated: 22 April 2026
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest independent biotechnology companies, with a mature portfolio of biologics across cardiovascular, bone health, inflammation, oncology and rare disease — and an increasingly ambitious pipeline targeting obesity, autoimmune conditions and small-cell lung cancer. The company closed 2025 with full-year revenue of $36.8 billion (up 10% year over year) and product sales of $35.1 billion, with 18 products hitting record annual sales and 14 crossing the $1 billion mark. Since closing its $27.8 billion acquisition of Horizon Therapeutics in October 2023, Amgen has been leaning heavily on rare-disease franchises — Tepezza, Krystexxa, Uplizna — to offset slowing growth in older blockbusters such as Enbrel, whose US exclusivity runs to 2029. The company's most-watched catalyst is MariTide, a monthly-dosed GLP-1/GIP asset in six Phase 3 studies under the MARITIME programme, which Amgen hopes can carve a differentiated position in the obesity market versus Eli Lilly and Novo Nordisk. This research report pulls together product sales, quarterly financials, pipeline milestones, insider activity and competitive context entirely from Amgen's filings and press releases — no analyst opinions, no price targets. For live pricing and broader market context, see our live charts, the economic calendar, and the community forum.
1. Company Snapshot
| Name | Amgen Inc. |
| Ticker | NASDAQ: AMGN |
| Sector | Healthcare & Pharmaceuticals (Biotechnology) |
| Headquarters | Thousand Oaks, California, USA |
| Founded | 1980 (as Applied Molecular Genetics Inc.) |
| CEO / Chairman | Robert A. Bradway (CEO since May 2012, Chairman since January 2013) |
| Employees | Approximately 28,000 (as disclosed by the company) |
| FY2025 Revenue | $36.8 billion (up 10% YoY) |
| FY2025 Product Sales | $35.1 billion (up 10% YoY) |
| FY2025 Non-GAAP EPS | $21.84 (up 10% YoY) |
| Free Cash Flow 2025 | $8.1 billion |
| Market Cap | Approximately $186 billion (21 April 2026) |
| Website | amgen.com |
2. Bull Case vs Bear Case
Bull Case
- Broad, diversified portfolio: 14 products with over $1 billion in annual sales in 2025 and 18 products at record annual sales, lowering single-drug concentration risk versus smaller biotechs.
- Growth products still ramping hard — Repatha +36% YoY in 2025, Tezspire +52%, Evenity +34%, Blincyto +28%, Uplizna +73%. Management highlights 13% volume growth in 2025 product sales.
- Rare disease franchise from the Horizon deal (Tepezza, Krystexxa, Uplizna, Tavneos) delivered growth in 2025 and anchors the strategy through the late-decade biosimilar exposure.
- MariTide (maripacibart) is in six global Phase 3 obesity studies (MARITIME programme) with Phase 2 data showing up to ~20% weight loss at 52 weeks with no plateau and monthly dosing — a potential convenience differentiator versus weekly GLP-1s.
- Repatha's VESALIUS-CV primary prevention data (31% MACE reduction in diabetic patients without established atherosclerosis, published March 2026) supports further label expansion and volume growth.
- Shareholder returns: 13 consecutive annual dividend increases, quarterly dividend of $2.52, $8.1 billion FCF in 2025, and a 2026 share-repurchase authorisation not to exceed $3 billion.
Bear Case
- Debt load is substantial: $54.6 billion of debt against $9.1 billion of cash at year-end 2025; leverage of 3.2x EBITDA remains elevated despite $6.0 billion of debt retirement in 2025.
- Enbrel US exclusivity ends in 2029; loss of exclusivity creates a meaningful revenue cliff for a product still generating multi-billion-dollar US sales.
- Prolia's 2025 full-year sales grew just 1% and Q4 sales fell 10% YoY on 8% lower net price — denosumab biosimilars are now a live pressure.
- Net selling prices fell 3% in 2025 on a full-year basis and 4% in Q4; volume (+13%) is doing the heavy lifting, which is the weaker foundation in biologics.
- MariTide enters a market already dominated by Eli Lilly's tirzepatide (roughly 57% of US GLP-1 prescriptions in late 2025) and Novo Nordisk's semaglutide; Amgen has no commercial position yet and Phase 3 readouts are a 2026/2027 event.
- Regulatory overhangs: Tavneos is in an ongoing dialogue with the FDA following a voluntary withdrawal request on data integrity concerns, and bemarituzumab has been deprioritised in first-line gastric cancer. A $1.2 billion Otezla intangible impairment was recorded in 2025.
3. What Does Amgen Actually Do?
Amgen discovers, develops, manufactures and sells human therapeutics — mostly biologics (proteins, antibodies, peptides, bispecifics) with a smaller small-molecule and biosimilar portfolio. Management runs the business around four therapeutic pillars plus a biosimilars business:
- General Medicine (~34% of product sales). Cardiovascular and bone-health franchises — Repatha (evolocumab, PCSK9 inhibitor for LDL cholesterol, $3.0B FY2025), Prolia (denosumab for osteoporosis, $4.4B), Evenity (romosozumab for osteoporosis, $2.1B), Otezla (apremilast for psoriasis/PsA, ~$2.3B). Repatha and Evenity are the growth engines here; Prolia is defending against biosimilar launches.
- Oncology (~25% of product sales, approximately $8.7B in 2025). Blincyto (blinatumomab bispecific for ALL, $1.6B, +28%), Imdelltra/tarlatamab (DLL3-targeted BiTE for small-cell lung cancer, $627M full year, +rapid ramp), Kyprolis, Vectibix, Nplate, Xgeva, Lumakras (KRAS G12C).
- Inflammation (~18%). Tezspire (tezepelumab, partnered with AstraZeneca for severe asthma, ~$1.5B and +52% YoY) and Enbrel ($2.2B, flat to declining; US exclusivity to 2029).
- Rare Disease (~14%). The Horizon-acquired portfolio: Tepezza (teprotumumab for thyroid eye disease, $1.9B), Krystexxa (pegloticase for chronic refractory gout, $1.3B +13%), Uplizna (inebilizumab for NMOSD and other indications, $655M +73%), Tavneos (avacopan for ANCA-associated vasculitis, ~$459M).
- Biosimilars (~9%, $3.0B in 2025, +37% YoY). Mvasi (bevacizumab), Kanjinti (trastuzumab), Amjevita (adalimumab), Riabni (rituximab), Wezlana (ustekinumab), Pavblu (aflibercept), Bkemv (eculizumab) — generic-style biologics that use Amgen's manufacturing scale.
US revenue remains the largest geographic bucket. Government payers (Medicare Part B and Part D, Medicaid) are significant indirect customers — particularly for older products like Prolia, Xgeva, Enbrel and Otezla — which exposes a portion of revenue to the Inflation Reduction Act's Medicare drug-price negotiation programme.
4. The Business Model
Amgen's core model is the classic branded-biologic playbook: invest heavily in R&D ($5.9B+ annual spend disclosed in recent filings), protect each product with a patent thicket and manufacturing know-how, and harvest high gross margins for the 12–20 years before biosimilars arrive. Non-GAAP gross margin was roughly 64–70% across 2025 quarters (reaching 69.8% in Q4 2025), and non-GAAP operating margin was 46.1% for the full year.
Key revenue drivers:
- Volume over price. Management has stated that 2025 product-sales growth was driven by 13% volume growth offset by 3% lower net price for the full year. Net pricing pressure is structural in US pharma and is likely to intensify as Medicare negotiation expands.
- Manufacturing scale. Amgen operates large-scale biologics manufacturing in the US (Thousand Oaks, Rhode Island, a new North Carolina facility announced as part of US capacity expansion) and in Puerto Rico, Ireland and the Netherlands. Biosimilars leverage the same infrastructure.
- Patent thicket. Enbrel's late-life protection is the most-cited example: layered patents have kept Samsung Bioepis and Sandoz biosimilars off the US market until 2029, more than 30 years after launch. Equivalent tactics are used across the portfolio.
- M&A as pipeline. The $27.8 billion Horizon acquisition (closed October 2023) added Tepezza, Krystexxa, Uplizna and Tavneos in one transaction. Management has stated it is targeting at least $500M in annual pre-tax cost synergies by the end of the third full year post-close and a return to pre-deal leverage by end-2025.
- Capital allocation. Dividend is the cornerstone (raised 13 years in a row, currently $2.52 quarterly / $10.08 annualised). 2026 share repurchases are authorised up to $3 billion, a modest step-up after the post-Horizon deleveraging. Capex guidance for 2026 is approximately $2.6 billion.
Amgen does not rely on government regulatory credits in the way that, say, EV or renewable-energy companies do. However, US government reimbursement via Medicare and Medicaid is material, and the IRA's drug-price-negotiation programme has already selected several widely used Amgen products for negotiated Medicare pricing, with implementation dates staggered across 2026 and 2027.
5. Financial Health
Five-year revenue and cash trend (Amgen press releases, 10-K filings)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| YoY growth | +2.2% | +1.3% | +7.1% | +18.6% | +10.0% |
| Free cash flow | ~$8.4B | ~$8.8B | $7.36B | $10.39B | $8.1B |
| Non-GAAP EPS | $17.10 | $17.69 | $18.65 | $19.84 | $21.84 |
| Debt (period-end) | ~$33B | ~$38B (pre-Horizon) | ~$64B (post-Horizon) | ~$60B | $54.6B |
| Cash & equivalents | ~$8.0B | ~$7.6B | ~$11.0B | ~$11.9B | $9.1B |
The 2023 step-up in revenue and debt reflects the Horizon acquisition, which was largely funded by $28 billion of bond issuance. Management retired $6.0 billion of debt in 2025, bringing year-end 2025 debt to $54.6 billion and leverage to 3.2x EBITDA.
Quarterly trend — last five quarters (source: Amgen earnings releases)
| Quarter | Total revenue | YoY | GAAP gross margin | Non-GAAP EPS |
|---|---|---|---|---|
| Q4 2024 | $9.09B | +11% | ~65.8% | $5.31 |
| Q1 2025 | $8.15B | +9% | ~63.6% | $4.90 |
| Q2 2025 | $9.18B | +9% | ~67.2% | $5.44 |
| Q3 2025 | $9.56B | +12% | ~67.8% | $6.21 |
| Q4 2025 | $9.87B | +9% | ~69.8% | $5.29 |
Q1 2026 results are scheduled for 30 April 2026 and are not included here. Management's 2026 guidance, issued with the Q4 2025 release on 3 February 2026, is total revenues of $37.0–38.4 billion, GAAP EPS of $15.45–16.94, and non-GAAP EPS of $21.60–23.00.
6. Valuation & Market Data
Figures below are pulled from public market data as of 21 April 2026 (last full trading day before publication). These are raw numbers for reference only — no commentary on cheap/expensive, no price targets.
| Metric | Value |
|---|---|
| Share price | $344.86 (close 21 Apr 2026) |
| Market capitalisation | $186.1B |
| Enterprise value | $232.4B |
| Shares outstanding | 539.7M |
| P/E (trailing, GAAP) | 24.2x |
| P/E (forward, company guidance midpoint) | ~15.4x |
| Price / Sales | 5.06x |
| EV / EBITDA | 13.99x |
| Price / Free Cash Flow | 22.98x |
| Dividend per share (annualised) | $10.08 ($2.52 quarterly) |
| Dividend yield | ~2.88% |
| Consecutive years of dividend increases | 13 |
| 52-week high | $391.29 (intraday) / $388.16 close on 27 Feb 2026 |
| 52-week low | $261.43 on 14 May 2025 |
| Short interest | 13.98M shares (~2.60% of float) |
| Days to cover | ~5.43 days |
| Data as of | 21 April 2026 |
7. What Are They Building?
Amgen's disclosed R&D pipeline spans obesity, oncology, rare disease, inflammation and general medicine. Below are the company-disclosed priorities.
| Programme | Indication / target | Phase / status | Notes |
|---|---|---|---|
| MariTide (maripacibart / AMG 133) | Obesity / overweight, Type 2 diabetes, ASCVD, HF, OSA | Phase 3 (MARITIME programme, six global studies) | Monthly subcutaneous dosing; Phase 2 showed up to ~20% weight loss at 52 weeks (obesity) and up to ~17% + 2.2 pp HbA1c drop (T2D); enrolling. |
| Repatha (evolocumab) | Primary prevention CV risk (diabetics without known ASCVD) | Phase 3 VESALIUS-CV read out March 2026 | 31% reduction in first major CV events in 3,655-patient diabetic subgroup over 4.8 years; label expansion effort. |
| Tepezza subcutaneous (teprotumumab) | Moderate-to-severe active thyroid eye disease | Phase 3 topline positive, 6 April 2026 | 77% proptosis response vs 19.6% placebo; 3.17mm mean reduction at week 24 via on-body injector. |
| Uplizna (inebilizumab) | Autoimmune hepatitis; chronic inflammatory demyelinating polyneuropathy (CIDP) | Phase 3 initiation planned 2026 | Already approved in NMOSD, IgG4-related disease and generalised myasthenia gravis. |
| Imdelltra (tarlatamab) | Extensive-stage SCLC (full FDA approval); frontline combo; limited-stage SCLC | Phase 3 (frontline & limited-stage) | FDA converted accelerated to full approval in late 2025; over 1,600 US sites using. |
| Blincyto (blinatumomab) | B-cell ALL — earlier lines, consolidation settings | Label expansion / ongoing studies | $1.6B FY2025 sales (+28%). |
| Bemarituzumab | Gastric cancer (FGFR2b+) | First-line programme deprioritised | Management exploring biomarker-defined subgroup signal; not pursuing 1L approval after FORTITUDE-101/102. |
| Tezspire (tezepelumab) | Chronic rhinosinusitis with nasal polyps (partnered with AstraZeneca) | FDA decision post Oct 2025 PDUFA | Asthma indication remains the volume driver. |
| Olpasiran | Elevated lipoprotein(a) | Phase 3 OCEAN(a) outcomes trial | Novel siRNA cardiovascular programme. |
| Rocatinlimab | Atopic dermatitis (OX40 antibody, with AstraZeneca) | Phase 3 ROCKET programme reported in 2025 | Mixed data profile; regulatory path under evaluation. |
Management has guided that R&D spend remains elevated in 2026 as MariTide Phase 3 studies carry full cost, and that 2026 capex of ~$2.6 billion reflects ongoing US manufacturing investment (including the previously announced new biologics plant in North Carolina).
8. Competitive Landscape
Amgen competes on multiple fronts depending on therapeutic area. Its most strategic future battleground is obesity, where it has no commercial product yet and where two incumbents control almost the entire market.
| Area | Main competitors | Amgen position |
|---|---|---|
| Obesity / GLP-1 | Eli Lilly (tirzepatide — Mounjaro/Zepbound), Novo Nordisk (semaglutide — Ozempic/Wegovy) | No product launched; MariTide in Phase 3 |
| Cardiovascular — PCSK9 | Regeneron/Sanofi (Praluent), Novartis (Leqvio / inclisiran siRNA) | Repatha: class leader on outcomes data; $3.0B FY2025, +36% |
| Osteoporosis | Radius Health (Tymlos), Lilly (Forteo), denosumab biosimilars (Sandoz, Celltrion) | Prolia/Evenity core; Prolia US biosimilar entry already weighing |
| Severe asthma | GSK (Nucala), AstraZeneca (Fasenra, co-commercialises Tezspire), Sanofi/Regeneron (Dupixent) | Tezspire partnership with AZ; $1.5B and +52% in 2025 |
| Small-cell lung cancer | AstraZeneca (Imfinzi), Roche (Tecentriq), Jazz (lurbinectedin) | Imdelltra is first-in-class DLL3 BiTE |
| Thyroid eye disease | None with approved drug | Tepezza is only FDA-approved TED drug |
| Inflammation (TNF class) | AbbVie (Humira), numerous biosimilar makers | Enbrel US exclusivity to 2029 |
US GLP-1 market share (approximate prescription share, late 2025, company disclosures and IQVIA data): Eli Lilly ~57%, Novo Nordisk ~43%, Amgen 0% (pre-launch). Charted below with Amgen highlighted for context.
9. Leadership and Ownership
Key executives (company disclosures)
| Name | Role |
|---|---|
| Robert A. Bradway | Chairman & CEO (CEO since May 2012; Chairman since Jan 2013). Amherst B.S., Harvard MBA; formerly Morgan Stanley healthcare banker. |
| Peter H. Griffith | Executive Vice President & Chief Financial Officer |
| James P. Bradner | Executive Vice President, Research & Development |
| Murdo Gordon | Executive Vice President, Global Commercial Operations |
| Esteban Santos | Executive Vice President, Operations |
Institutional ownership (most recent 13F filings): institutions hold approximately 81% of AMGN shares.
| Holder | Shares | % out |
|---|---|---|
| Vanguard Group | ~53.6M | ~9.96% |
| State Street Investment Management | ~29.3M | ~5.44% |
| BlackRock Institutional Trust | ~28.5M | ~5.30% |
| Capital World Investors / Capital International | Reported as top-10 each | — |
| Geode Capital Management, Morgan Stanley, Charles Schwab IM | Top-10 institutions | — |
Recent insider activity (Form 4 filings, last 12 months): Insider activity has been dominated by tax-withholding on vested restricted stock units and routine option exercises. A public-interest marker: CEO Bradway exercised options on 119,782 shares at $156.35 (strike) in a recent filing, with 84,285 shares withheld for taxes — a derivative exercise rather than an open-market purchase. A later Form 4 reports a further 21,294 shares withheld for tax on RSU vesting, leaving Bradway with ~501,862 shares directly held plus ~90,000 held via a GRAT structure. There are no material discretionary open-market buys by named executive officers disclosed in the last 12 months; the sells visible have been consistent with 10b5-1 plans or tax-withholding automatics.
10. Risks and Challenges
- Enbrel patent cliff 2029. US biosimilar entry for Samsung Bioepis and Sandoz is blocked until 2029; the full revenue impact will hit 2029–2031 and requires growth products to be materially larger by then.
- Prolia denosumab biosimilars. Already launched in the US; 2025 Prolia growth slowed to 1% and Q4 declined 10% on an 8% lower net selling price. Evenity partially offsets but is a different market (severe osteoporosis patient subgroup).
- Medicare drug-price negotiation (IRA). Several Amgen products are within scope; negotiated prices for some products take effect in 2026/2027 and will directly compress net price on US Medicare volume.
- Obesity competition. Lilly's tirzepatide already holds ~57% of US GLP-1 prescriptions; Novo Nordisk holds the rest. Amgen enters with MariTide no earlier than 2027 and will need to defend a monthly-dosing claim against potential oral and once-monthly programmes from competitors.
- Debt and interest expense. $54.6 billion of debt and 3.2x EBITDA leverage constrain capital allocation; large additional M&A would re-leverage.
- Regulatory and data integrity issues. Tavneos faces an FDA voluntary-withdrawal request over data integrity concerns; bemarituzumab first-line development has been deprioritised; Otezla required a $1.2 billion intangible impairment in 2025.
- Pipeline concentration on MariTide. MariTide is the single largest near-term share-price catalyst. Six Phase 3 studies over multiple patient populations carry high cost and binary-risk overhang.
- Volume vs price mix. 2025 product-sales growth was 13% volume / –3% price. Continued reliance on volume requires successful indication expansion and launch execution on newer products.
- Manufacturing complexity. Biologics supply chains have less tolerance for disruption than small-molecule lines; any major site issue would be material.
- Macro / FX. Approximately a quarter of sales are non-US; dollar strength weighs on reported growth.
11. Recent Developments
- 6 April 2026 — Subcutaneous Tepezza Phase 3 positive. Amgen announced positive topline Phase 3 results for a subcutaneous, on-body-injector formulation of Tepezza in moderate-to-severe active thyroid eye disease: 77% proptosis response rate vs 19.6% placebo over 24 weeks, mean proptosis reduction of 3.17mm; overall safety consistent with the IV profile.
- 28 March 2026 — Repatha VESALIUS-CV primary-prevention subgroup. In a 3,655-patient subgroup of diabetics without known significant atherosclerosis followed for a median 4.8 years, Repatha cut first major CV events by 31% (3-P and 4-P MACE); median LDL-C at 96 weeks was 44 mg/dL vs 105 mg/dL placebo. Simultaneously published in JAMA.
- 4 March 2026 — Q2 2026 dividend declared. $2.52 per share, payable 5 June 2026 to shareholders of record 15 May 2026 — Amgen's 13th consecutive annual increase.
- 3 February 2026 — Q4 and full-year 2025 results. Revenue $9.9B in Q4 (+9%), $36.8B for FY2025 (+10%), non-GAAP EPS $21.84, GAAP EPS $14.23. 2026 revenue guidance $37.0–38.4B, non-GAAP EPS $21.60–23.00. $8.1B FCF; $6.0B of debt retired in 2025.
- Nov 2025 — VESALIUS-CV main study. Amgen first reported that Repatha reduced first major CV events by 25% in the full 12,301-patient trial; the diabetic subgroup analysis above is a follow-on.
- Nov 2025 — Q3 2025 results. Revenue $9.6B (+12%); Imdelltra $178M (+33% QoQ); rare disease +13%, biosimilars +52%.
- Jun 2025 — MariTide Phase 2 update at ADA. Up to ~20% weight loss at 52 weeks in obesity (no plateau); up to ~17% weight loss and 2.2 pp HbA1c reduction in T2D.
- Earlier 2025 — Imdelltra FDA full approval in extensive-stage small-cell lung cancer; Uplizna label-expansion momentum; Tavneos FDA voluntary-withdrawal request filed on 16 January 2026 (data integrity concerns — ongoing dialogue).
12. Key Dates Coming Up
- 30 April 2026 — Q1 2026 earnings release and conference call (after market close; call at 1:30 PM PDT).
- May 2026 (annual meeting window) — Amgen's 2026 Annual Meeting of Stockholders.
- 15 May 2026 — Q2 2026 dividend record date.
- 5 June 2026 — Q2 2026 dividend payment date ($2.52).
- 2026–2027 — Expected Phase 3 MARITIME readouts for MariTide in obesity (MARITIME-1) and overweight/T2D (MARITIME-2); additional Phase 3 studies in ASCVD, heart failure and obstructive sleep apnea ongoing.
- 2026 — Planned initiation of Phase 3 Uplizna studies in autoimmune hepatitis and CIDP.
- 2026 — Regulatory filing activity expected around subcutaneous Tepezza following positive Phase 3 topline.
- 2029 — US loss of exclusivity for Enbrel (biosimilar entry window opens).
Related
For live charts and watchlist tools, see our live charts. Macro and US data releases that move healthcare names are on the economic calendar. Discuss this report in the community forum, and browse more company research in our blog.
Disclaimer: Research only. This article is for information and discussion purposes. It is not investment advice, not a recommendation to buy or sell any security, and does not take your personal circumstances into account. All financial figures come from Amgen company filings and press releases; market data is as of the dates stated. Always do your own research and consult a qualified adviser before making investment decisions.